1. Crizotinib may be used in Lewis lung carcinoma: A novel use for crizotinib
   PU XIA et al, 2013 CrossRef
2. Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer
   Ying Dai et al, 2015, Radiotherapy and Oncology CrossRef
3. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization
   Poushali Bhattacharya et al, 2018, International Journal of Radiation Biology CrossRef
4. Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.
   Andrei Laszlo et al, 2013, Cancer J CrossRef
5. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
   Robert Roskoski, 2013, Expert Opinion on Drug Discovery CrossRef
6. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.
   James E Frampton, 2013, Drugs CrossRef
7. RANK-mediated signaling network and cancer metastasis.
   Gina Chia-Yi Chu et al, 0 CrossRef
8. Concurrent crizotinib and whole-brain radiation for brain metastases in ALK-positive lung adenocarcinoma
   Ian G Pinto et al, 2014, Lung Cancer Management CrossRef
9. Molecular Determinants of Radiation Response in Non–Small Cell Lung Cancer
   Sue S. Yom et al, 2015, Seminars in Radiation Oncology CrossRef
10. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer
    Abigail R. Bland et al, 2019, European Journal of Pharmacology CrossRef
11. The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
    Céline Clémenson et al, 2017, Mol Cancer Ther CrossRef
12. FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer
    Kylie A. McLaughlin et al, 2016, Mol Cancer Ther CrossRef
13. The E3 Ligase CHIP Mediates p21 Degradation to Maintain Radioresistance
    Kuntal Biswas et al, 2017, Mol Cancer Res CrossRef
14. Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases
    Andrew M. Baschnagel et al, 2021, Sci Rep CrossRef
15. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
    Delphine Antoni et al, 2021, Cancers CrossRef
16. A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer
    Javier Peinado-Serrano et al, 2022, Cancers CrossRef
17. Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients
    Tina Jost et al, 2022, Strahlenther Onkol CrossRef
18. Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors
    Javier Peinado-Serrano et al, 2022, Cancers CrossRef
19. The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma
    Malak Sabbah et al, 2023, Front. Med. CrossRef
20. null
    Rodolfo Chicas-Sett et al, 2023 CrossRef
21. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
    Shrey Ramesh et al, 2023, International Journal of Radiation Oncology*Biology*Physics CrossRef